ArticleRheumatology (Oxford, England)2020

Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia.

Raj Amarnani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.